Jinshi Data December 20 News, Koyuan Pharmaceutical announced that the company plans to purchase 99.42% of the equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. held by 39 trading counterparts such as Lino Investment Holding Group Co., Ltd., Lino Group Co., Ltd., and pay cash. At the same time, the company plans to raise matching funds from no more than 35 specific objects to produce shares. This transaction constitutes a related party transaction, a major asset restructuring, but not a restructuring listing. As of the disclosure date of this announcement, due diligence, audit, assessment or valuation work related to this transaction is in progress.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Koyuan Pharmaceuticals: Plans to acquire 99.42% equity of Hongji Tang
Jinshi Data December 20 News, Koyuan Pharmaceutical announced that the company plans to purchase 99.42% of the equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. held by 39 trading counterparts such as Lino Investment Holding Group Co., Ltd., Lino Group Co., Ltd., and pay cash. At the same time, the company plans to raise matching funds from no more than 35 specific objects to produce shares. This transaction constitutes a related party transaction, a major asset restructuring, but not a restructuring listing. As of the disclosure date of this announcement, due diligence, audit, assessment or valuation work related to this transaction is in progress.